Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600765 | 0.93 | ALDH1A1 (0.48) | LMNASMN1; SMN2ALDH1A1KDM4EMCL1 | |
| SCHEMBL2177234 | 0.82 | MAPK14 (0.44) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2178094 | 0.81 | EPHX2 (0.47) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2175595 | 0.81 | MAPK14 (0.43) | LMNASMN1; SMN2ALDH1A1TSHRTDP1 | |
| SCHEMBL2177202 | 0.80 | MAPK14 (0.53) | — | |
| SCHEMBL2178830 | 0.80 | MAPK14 (0.42) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2177043 | 0.79 | MAPK14 (0.41) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2175907 | 0.79 | MAPK14 (0.41) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2177627 | 0.79 | MAPK14 (0.41) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2175946 | 0.79 | LMNA (0.46) | LMNASMN1; SMN2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | LMNA 1691/4885SMN1; SMN2 4359/4885ALDH1A1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.